Treatment

Currently there is no approved treatment for acute or chronic HDV infection. Pegylated interferon alpha is the only drug that has been shown to be somewhat effective against HDV. It acts by stimulating the body's immune system to get rid of the virus. A small percentage (<30%) experience remission when injected weekly over 48 weeks. Oral nucleosides approved for hepatitis B have been used for HDV if interferon therapy is not possible and there is a high hepatitis B viral load. But these have not been very effective.

Currently, there is more hope for people diagnosed with Hepatitis D with promising new drugs in development. For more information about clinical trials click here

Drugs in Development for Hepatitis D

HDV Drug Watch New

Pegylated Interferon Lambda

Pegylated-interferon-lambda (PEG-IFN-λ) is a well-characterized, late-stage, first in class, type III interferon that stimulates cell-mediated immune responses that are critical for the development of host protection during viral infections. This drug is now granted "Orphan Drug Designation" by the FDA.

Myrcludex B

This drug is an “entry inhibitor” that inhibits virus entry into hepatocytes (liver cells) and has shown activity against the hepatitis B virus. It may also hinder the establishment of HDV infection by breaking the cycle of infection of the liver cell and possibly re-infection. A recent study showed promise for Myrcludex B when combined with PEG-INF in reducing hepatitis D viral levels.

Lonafarnib

This drug works by targeting the protein assembly process, preventing the production of new virus particles. In a current clinical trial, Lonafarnib combined with Ritonavir has shown promise in reducing hepatitis D viral levels, and the FDA has granted it fast-track status since this class of drugs have been developed for the treatment of cancers and have been shown to be safe.

Rep 2139

This compound is known as a “Nucleic acid-based Amphipathic
Polymer” (NAP) which inhibits the release of hepatitis B surface antigen (HBsAg) from infected liver cells and is being evaluated for hepatitis D virus in combination with PEG IFN.

GI-18000

The company has the potential to develop its GI-18000 Tarmogen to cause a T cell immune response against cells infected with HDV and thereby improve outcomes. Globeimmune’s strategy is to identify molecular targets that distinguish diseased cells from normal cells and activate the immune system to selectively target and eliminate only the diseased cells. 

ALN-HDV

This approach is being used for both the hepatitis B and hepatitis D virus to  "silence" the viral RNA with compounds that interfere with and cause the destruction of the viral genome (e.g. stop replication of the virus). 

For current clinical trials for Hepatitis D click here.